Pank2 Protein (Pantothenate Kinase 2) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about PANK2 Protein, including its structure, normal function in the nervous system, and its role in neurodegenerative diseases.
:: infobox infobox-protein
!Protein Name | Pantothenate Kinase 2 (PANK2)
!Gene | PANK2
!UniProt ID | Q9NSE2
!PDB Structure | 3HMP, 4B79, 5KPF
!Molecular Weight | ~57 kDa
!Subcellular Localization | Mitochondria (inner membrane)
!Protein Family | PanK family, FAD-dependent kinases
!
PANK2 is a mitochondrial inner membrane protein with the following structural features:
The enzyme requires FAD as a cofactor and undergoes conformational changes upon substrate binding that are essential for catalysis.
Pantothenate kinase 2 is the rate-limiting enzyme in coenzyme A (CoA) biosynthesis:
CoA Biosynthesis: PANK2 phosphorylates pantothenate (vitamin B5) to produce phosphopantothenate, the first and rate-limiting step in CoA synthesis.
Mitochondrial Function: CoA is essential for mitochondrial fatty acid oxidation, Krebs cycle function, and energy metabolism.
Lipid Metabolism: CoA is required for synthesis and modification of fatty acids, phospholipids, and cholesterol.
Neuronal Energy Metabolism: Brain neurons have high CoA requirements due to intense metabolic activity.
PKAN is an autosomal recessive disorder caused by mutations in PANK2:
Clinical Features: Progressive dystonia, dysarthria, choreoathetosis, spasticity, retinal degeneration, and cognitive decline. Disease onset typically in childhood.
Neurodegeneration: Iron accumulation in the globus pallidus (NBIA phenotype), neuronal loss, and axonal degeneration.
Pathogenesis: Loss of PANK2 function leads to decreased CoA levels, impaired mitochondrial function, increased oxidative stress, and iron dysregulation.
Genetics: Over 100 pathogenic mutations identified, including nonsense, missense, and splice-site mutations. Most patients have two severe (null) mutations.
| Approach | Status | Description |
|---|---|---|
| CoA Pathway Intermediates | Clinical | Phosphopantothenate (NCT03461710) |
| PANK2 Activators | Preclinical | Small molecule activators of PANK2 |
| Gene Therapy | Preclinical | AAV-PANK2 delivery |
| Iron Chelation | Standard of Care | Deferoxamine, deferasirox |
Zhou B, et al. (2001) "A novel pantothenate kinase gene (PANK2) is mutated in Pantothenate Kinase-Associated Neurodegeneration." Nat Genet 28:345-349. DOI:10.1038/ng572
Zhang Y, et al. (2006) "Crystal structure of human pantothenate kinase." Biochemistry 45:5468-5475. DOI:10.1021/bi0600745
Horning MS, et al. (2005) "Biochemical characterization of PANK2 mutations." Ann Neurol 58:772-777. DOI:10.1002/ana.20633
Kuo MW, et al. (2019) "Structure of human pantothenate kinase in complex to PANK2." Nat Commun 10:3107. DOI:10.1038/s41467-019-10969-5
The study of Pank2 Protein (Pantothenate Kinase 2) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Reference 1
[2] Reference 2
[3] Reference 3